ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Ramaiah KD, Ottesen EA, 2014. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis 8: e3319.
-
2.
World Health Organization, 2013. Meeting of the International Task Force for Disease Eradication–November 2012. Wkly Epidemiol Rec 88: 75–80.
-
3.
Vincent AL, Gonzalvo A, Cowell BC, Nayar JK, Uribe L, 1987. A survey of Bancroftian filariasis in the Dominican Republic. J Parasitol 73: 839–840.
-
4.
Nutman TB, 2013. Insights into the pathogenesis of disease in human lymphatic filariasis. Lymphat Res Biol 11: 144–148.
-
5.
Person B, Bartholomew LK, Addiss D, van den Borne B, 2007. Disrupted social connectedness among Dominican women with chronic filarial lymphedema. Patient Educ Couns 68: 279–286.
-
6.
World Health Organization, 2011. Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. Geneva, Switzerland: WHO.
-
7.
Oscar R, Lemoine JF, Direny AN, Desir L, Beau de Rochars VE, Poirier MJ, Varghese A, Obidegwu I, Lammie PJ, Streit TG, Milord MD, 2014. Haiti national program for the elimination of lymphatic filariasis-a model of success in the face of adversity. PLoS Negl Trop Dis 8: e2915.
-
8.
Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, Kumar A, Kazura JW, 2004. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 4: 223–234.
-
9.
Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD, 2003. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 188: 1371–1381.
-
10.
Chernin E, 1987. The disappearance of bancroftian filariasis from Charleston, South Carolina. Am J Trop Med Hyg 37: 111–114.
-
11.
Wamae CN, Njenga SM, Ngugi BM, Mbui J, Njaanake HK, 2011. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Trop 120 (Suppl 1): S33–S38.
-
12.
Makunde WH, Kamugisha LM, Massaga JJ, Makunde RW, Savael ZX, Akida J, Salum FM, Taylor MJ, 2003. Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis. Filaria J 2: 15.
-
13.
Critchley J, Addiss D, Ejere H, Gamble C, Garner P, Gelband H, IFR Group, 2005. Albendazole for the control and elimination of lymphatic filariasis: systematic review. Trop Med Int Health 10: 818–825.
-
14.
Pion SD, Chesnais CB, Bopda J, Louya F, Fischer PU, Majewski AC, Weil GJ, Boussinesq M, Missamou F, 2015. The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo. Am J Trop Med Hyg 92: 959–966.
-
15.
World Health Organization, 2010. Report of the Third Global Scientific Meeting on Trachoma Elimination. Geneva, Switzerland: WHO.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1 | 1 | 1 |
| Full Text Views | 345 | 138 | 0 |
| PDF Downloads | 89 | 50 | 0 |
Post-Mass Drug Administration Transmission Assessment Survey for Elimination of Lymphatic Filariasis in La Ciénaga, Dominican Republic
The Dominican Republic is one of four remaining countries in the Americas with lymphatic filariasis (LF). Annual mass drug administration (MDA) with albendazole and diethylcarbamazine was conducted in La Ciénaga, an impoverished urban barrio in Santo Domingo, from 2004 to 2006. Eight years after the last MDA, a transmission assessment survey (TAS) was conducted in November–December 2014 to determine if LF transmission remains absent. Of 815 first and second grade primary school students (mean age: 6.51 years; range 5–9) tested by immunochromatographic test (ICT), zero (0.0%) were positive. This is below the TAS critical cutoff of nine, indicating that the area “passed” TAS and that transmission remains interrupted in La Ciénaga. Importantly, this also provides evidence that three rounds of effective (> 65% coverage) MDA, likely aided by environmental improvements and periodic school-based albendazole monotherapy MDA, achieved interruption of LF transmission from a relatively low-transmission setting.
Author Notes
Financial support: This survey was funded in part by The Carter Center and the Pan American Health Organization.
Authors' addresses: Gregory S. Noland and Stephen Blount, The Carter Center, Atlanta, GA, E-mails: gregory.noland@cartercenter.org and stephen.blount@cartercenter.org. Manuel Gonzalez, Centro de Control de Enfermedades Tropicales, Santo Domingo, Dominican Republic, E-mail: manuelgonpe@gmail.com.